Radio therapy can lead to severe and longstanding lymphopenia, but he risk factors for lymphopenia and its complications are not well elucidated.
Radio therapy can lead to break down of normal body barriers and associated defense mechanisms against invading microbes and microbial products.
The technologies for delivering radiotherapy to the target tumours and minimize the radiation delivered toi the surrounding healthy tissue have developed dramatically over the last decade. The benefit of the technology shift on patient outcome in terms of disease-free survival and complications is poorly documented.
To bring together in a SIG radiotherapy, immunological and clinical expertise for the development of designs that combine data from planning, delivery and actual measurement of radiotherapy with paraclinical and patient outcome data, including infectious complications
To design projects – retrospective and prospective – that analyse radiotherapy delivery versus immunodeficiency and infectious complications.
To develop algorithms for surveillance of immunodeficiency and threats of opportunistic infections in patients undergoing radiotherapy, depending on target organ, concomitant therapy and comorbidity.